Cipla News, Corporate filings and Earnings/Conference Calls

Keep track of all breaking news and updates on Cipla from all sources in a single place.

Cipla Ltd.

28 Sep 2026

1339.50

-0.48%

Board Meeting

Cipla Ltd - 500087 - Board Meeting Intimation for The Quarter And Half Year Ended 30Th …

BSE India

Cipla Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 27/10/2026 ,inter alia, to consider and approve the unaudited standalone and consolidated financial results for the quarter and half year ended 30th September, 2026. In terms of the Company''s Code of Conduct for prevention of Insider Trading, the ''''Trading window'''' for dealing in the securities of the Company will be closed from Thursday, 1st October, 2026 till Thursday, 29th October, 2026 (both days inclusive) for the purpose of financial results.

pdf

Cipla Ltd.

28 Sep 2026

1339.50

-0.48%

Board Meeting

Cipla Ltd - 500087 - Board Meeting Intimation for The Quarter And Half Year Ended 30Th …

BSE India

pdf

Cipla Ltd.

24 Sep 2026

1339.50

-0.48%

Company Update

Cipla Ltd - 500087 - Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS

BSE India

In terms of Regulation 30 of SEBI (LODR) Regulations, 2015, we hereby notify that the Operations and Administrative Committee of the Company on 24th September, 2026 has allotted 12,168 fully paid up equity shares of INR 2 each pursuant to exercise of employee stock options/ stock appreciation rights under the Employee Stock Option Scheme 2013-A and Cipla Employee Stock Appreciation Rights Scheme 2021 of the Company.

pdf

Cipla Ltd.

22 Sep 2026

1339.50

-0.48%

Company Update

Cipla Ltd - 500087 - Announcement under Regulation 30 (LODR)-Change in Management

BSE India

Please find enclosed disclosure relating to the Change in SMP.

pdf

Cipla Ltd.

18 Sep 2026

1339.50

-0.48%

Company Update

Cipla Ltd - 500087 - Intimation Under Regulation 30 Read With Schedule III Of The SEBI …

BSE India

Please find enclosed disclosure on ESG Rating.

pdf

Cipla Ltd.

04 Sep 2026

1339.50

-0.48%

Cipla slips after Qilu Pembrolizumab deal; Morgan Stanley flags crowded field

Business Line

Cipla stock trades at 1,388, down 0.48% or 6.70 from its previous close of 1,394.70

Cipla Ltd. is trading below all available SMAs

Cipla Ltd.

04 Sep 2026

1339.50

-0.48%

Cipla partners with Qilu to license, supply Keytruda biosimilar in US

Business Standard

Drug major Cipla Ltd on Thursday said its wholly owned subsidiary, Invagen Pharmaceuticals Inc, has entered into a strategic partnership with Qilu Pharmaceutical for the licensing and supply of a biosimilar to the cancer drug Keytruda in the United States. The product, QL2107, is a biosimilar to pembrolizumab (Keytruda) and aims to improve access to advanced therapies for cancer patients while lowering treatment costs, Cipla said in a regulatory filing. Under the agreement, Qilu will be responsible for the development, regulatory registration, and supply of the product, while Cipla will leverage its commercial presence to market the asset in the US. "This partnership reflects Cipla's confidence in the long-term potential of biosimilars and supports our strategy to build a strong oncology-focused portfolio," said Achin Gupta, Managing Director and Global Chief Executive Officer, Cipla. Hanchang Zhang, General Manager of Qilu Pharmaceutical, said, "We are pleased to establish this ..

Number of FII/FPI investors decreased from 964 to 917 in Jun 2026 qtr

Cipla's US subsidiary partners with Qilu for Keytruda biosimilar

Business Line | 04 Sep 2026

Cipla Ltd.

03 Sep 2026

1339.50

-0.48%

Company Update

Cipla Ltd - 500087 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

BSE India

Please find enclosed press release titled ''Cipla Announces Exclusive Partnership with Qilu Pharmaceutical for the Licensing and Supply of Biosimilar to Keytruda (Pembrolizumab) in the US''

pdf